Bile Acid Metabolism Subtypes Mark Prognosis in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, with more than two million new cases and nearly one million deaths annually. Despite advances such as immune checkpoint inhibitors (ICIs), only a subset of CRC patients achieve durable responses, often due to primary resistance mechanisms. A growing body of evidence has implicated bile acid metabolism not only in lipid digestion but also in tumorigenesis, inflammation, and immune regulation within the gastrointestinal tract. However, the specific contribution of bile acid metabolism to the immune landscape and prognosis of CRC has not been fully elucidated.

Feng et al. address this gap by investigating whether molecular subtypes of CRC defined by bile acid metabolism pathways can predict clinical outcomes and immune dysfunction. Their central question: can bile acid metabolic signatures be leveraged to identify robust prognostic and immune-related biomarkers in CRC?

Key Innovation from the Reference Study

The core innovation of Feng et al. (2026) is the application of integrative transcriptomic analysis to classify CRC tumors based on bile acid metabolism gene expression. By partitioning patients into distinct molecular subtypes, the study directly links metabolic reprogramming to the tumor immune microenvironment (TIME) and survival outcomes. Notably, the identification of three hub genes—CLCA1, UGT2A3, and ZG16—as markers of immune dysfunction and poor prognosis represents a significant advance for CRC biomarker research. The study also demonstrates that these markers are reproducible across multiple datasets and independent clinical samples.

Methods and Experimental Design Insights

Feng et al. utilized transcriptomic and clinical data from the TCGA-Colon Adenocarcinoma (TCGA-COAD) cohort as a discovery set. The workflow included:

• Unsupervised consensus clustering of gene expression profiles linked to bile acid metabolism, generating molecular CRC subtypes.
• Survival analysis comparing overall survival (OS) between subtypes.
• Immune infiltration estimation using bioinformatic deconvolution methods to quantify CD8+ T cells, M1 macrophages, and other immune subsets.
• Differential gene expression analysis to identify genes distinguishing subtypes.
• Protein–protein interaction (PPI) network and Cox regression to pinpoint hub genes associated with survival.
• Validation of hub gene expression in GEO datasets and independent clinical CRC samples.

This multifaceted approach ensured both statistical rigor and biological relevance in biomarker discovery.

Core Findings and Why They Matter

Major findings from the study include:

• Bile acid metabolism subtypes predict prognosis: Patients classified as "bile-low" exhibited significantly shorter OS (p = 0.0049) compared to "bile-high" patients.
• Immune infiltration patterns: The bile-low group showed increased infiltration of CD8+ T cells (p < 0.05) and M1 macrophages (p < 0.01), suggesting a distinct immune microenvironment.
• Identification of three hub genes: CLCA1, UGT2A3, and ZG16 were downregulated in CRC tumor tissues across both TCGA-COAD and GEO datasets, as well as in independent clinical samples.
• Prognostic significance: High expression of CLCA1 was significantly associated with favorable OS (p < 0.001); UGT2A3 and ZG16 did not reach statistical significance for OS.
• Negative correlation with TIDE score: All three hub genes were inversely correlated with Tumor Immune Dysfunction and Exclusion (TIDE) scores, supporting their relevance to immune escape mechanisms (CLCA1: R = −0.24, p < 0.001).

These findings support the hypothesis that bile acid metabolism orchestrates changes in the TIME, with direct implications for patient stratification and prognosis in CRC. The reproducibility of the hub gene markers across datasets strengthens their potential utility as clinical biomarkers.

Comparison with Existing Internal Articles

Internal resources have previously addressed bile acid metabolism subtyping and biomarker discovery in CRC—for example, "Bile Acid Metabolism Subtypes and Prognostic Markers in Colorectal Cancer" and "Bile Acid Metabolism Subtypes Identify Prognostic Markers in CRC"—both summarize the integrative approach pioneered by Feng et al. and reinforce the significance of CLCA1, UGT2A3, and ZG16 in immune dysfunction and prognosis. Additionally, another review underscores the importance of linking metabolic signals to the TIME for improved biomarker-driven stratification.

These internal summaries are consistent with the present study, highlighting strong consensus on the value of bile acid metabolism signatures for both basic research and translational applications. The convergence of independent analyses on the same hub genes further validates their role in CRC biology.

Limitations and Transferability

Despite its strengths, the study has several limitations:

• Cohort composition: The discovery and validation cohorts are predominantly retrospective and may not capture the full heterogeneity of CRC across global populations.
• Functional validation: While bioinformatic and expression analyses are robust, direct experimental validation of the mechanistic roles of CLCA1, UGT2A3, and ZG16 in modulating the TIME is limited.
• Clinical translation: The markers identified require prospective evaluation before routine clinical use for patient stratification or therapeutic guidance.

Nevertheless, the analytical framework is transferable to other tumor types characterized by metabolic heterogeneity and immune modulation, pending validation.

Protocol Parameters

• RNA Extraction and Quality Assessment: Use high-integrity RNA from freshly frozen or adequately preserved tissue to maximize transcript detection accuracy in CRC biomarker assays.
• Reverse Transcription: Employ a reverse transcriptase with enhanced fidelity and efficiency, especially for low-concentration and high-GC content RNA, to ensure quantitative detection of CLCA1, UGT2A3, and ZG16 transcripts.
• gDNA Contamination Removal: Incorporate a genomic DNA removal step prior to cDNA synthesis to prevent false-positive signals in downstream qPCR.
• qPCR Primer Design: Optimize primers for regions with varying GC content and validate for specificity to each hub gene.
• Reference Gene Selection: Confirm stable expression of housekeeping genes in the context of metabolic and immune perturbations.

Research Support Resources

For researchers aiming to reproduce or extend these findings, robust reverse transcription and precise gene expression quantification are essential. The HyperScript™ III RT SuperMix for qPCR (with gDNA wiper) (SKU K1585) offers high efficiency for reverse transcription of low-concentration RNA, effective genomic DNA contamination removal, and reliable performance with high-GC content RNA templates, as described in the product information. This supports accurate gene expression analysis by qPCR, particularly for low-abundance markers such as CLCA1, UGT2A3, and ZG16.